Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Announcement & MannKind Corporation (MNKD)’s New Options

Page 1 of 2

Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD), J.C. Penney Company, Inc. (NYSE:JCP)

3 Pharmaceutical Stocks to Sell Now (InvestorPlace)
This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). This week, VIVUS, Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. The stock price has dropped 17.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time.


Eye Catching Stocks for Friday’s Trading Session: Arena Pharmaceuticals Inc (ARNA), J.C. Penney Company Inc (JCP) (SBWire) issues special report on – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), J.C. Penney Company, Inc. (NYSE:JCP) Arena Pharmaceuticals Inc (NASDAQ: ARNA) may have triggered an individual to create heart disease in an early-stage medical query, the company refers to, one day after introducing there had not been any serious adverse reactions during the research. Arena Pharmaceuticals, Inc. (ARNA) after opening at $6.55 hit a high price of $6.58 and then closed at $6.35 by declining -5.08% and on last session volume of 8.68 million shares was surprisingly lower than its average volume of 4.24 million shares.

MannKind Corp. VP Unloads $110,999.12 in Stock (MNKD) (WatchlistNews)
MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 19,204 shares of MannKind Corp. stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $5.78, for a total transaction of $110,999.12. Following the sale, the vice president now directly owns 40,082 shares in the company. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. A number of analysts have recently weighed in on MNKD shares. Analysts at MLV Capital raised their price target on shares of MannKind Corporation (NASDAQ:MNKD).

Commit To Purchase Vivus At $8, Earn 17.1% (Forbes)
Investors considering a purchase of VIVUS, Inc. (NASDAQ:VVUS) shares, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $8 strike, which has a bid at the time of this writing of $1.37. Collecting that bid as the premium represents a 17.1% return against the $8 commitment, or a 12.3% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Arena Reports Closing of Phase 1b Clinical Trial for APD811; Astex Shares On Watch Following Positive Top-Line Data for SGI-0110 (HispanicBusiness)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. “Arena’s internal GPCR-focused efforts led to the discovery of this novel drug candidate,” said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer…

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!